Editas Medicine Appoints Judith Abrams Chief Medical Officer

Judith Abrams has joined Editas Medicine as (NASDAQ: [[ticker:EDIT]]) chief medical officer. She most recently worked at EMD Serono Research and Development Institute as the franchise lead in immunology and neurology, global drug safety innovation. Her experience includes positions at CorMedix, Celgene (NASDAQ: [[ticker:CELG]]), and Novo Nordisk (NYSE: [[ticker:NVO]]). Cambridge, MA-based Editas is developing gene-editing therapies based on the CRISPR technology. The company’s lead drug candidate, EDIT 101, is currently in Phase 1 testing as a potential treatment for a rare, genetic form of vision loss.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.